Array Bridge Inc. was founded by scientists with extensive experience in drug discovery and biologics development. Array Bridge provides products and services that address two important areas in the development of biologics: biosimilar drug comparability analysis and impurity analysis.

Array Bridge has developed "antibody arrays" to measure biosimilar drug comparability at the molecular level, providing a sensitive, systematic and robust measurement of biosimilar conformational comparability. This antibody array-based technology can be used at all stages of biosimilar development, from cell line selection and process development to clinical testing and product release.

For impurity analysis, Array Bridge provides ELISA kits and reagents for Host Cell Protein quantitation and Western Blot analysis. All the products are manufactured under cGMP to ensure quality and consistency.

Array Bridge provides quality products and services for the pharmaceutical and biotechnology industry. Products and services include:

· Antibody arrays for biosimilar three-dimensional (3-D) conformational comparability analysis

· Antibody arrays for antibody-drug conjugate (ADC) three-dimensional (3-D) conformational comparability analysis

· CHO and E.coli Host Cell Protein Elisa kits

· Antibody production

· Host Cell Protein and binding –based bioassay method qualification and validation

· 1-D and 2-D gel analysis of process-related impurities

· Western Blot analysis of HCPs and Residual DNA and Protein A analysis

· Residual DNA and Protein A analysis

2010